Oncostellae

Pipeline

Pipeline

OST-122     (IBD, fibrosis)

Oral, non-systemic JAK3/TYK2-ARK5 inhibitor

DISCOVERY 100%
PRECLINICAL 100%
PHASE I 100%
PHASE IIa 100%

OST-499  (Uterine fibroids. Colon cancer)

Oral, non-steroidal PR/GR antagonist

DISCOVERY 100%
PRECLINICAL 100%
PHASE I 50%
PHASE II 0%

OST-664 (Fibrosis)
Oral ARK5 inhibitor

DISCOVERY 70%
PRECLINICAL 0%
PHASE I 0%
PHASE II 0%

OST-122

Our lead program is a safer, non-systemic JAK inhibitor, OST-122, which is being developed as a local treatment for IBD (inflammatory bowel disease). Orally administered, OST-122 acts exclusively in the gastrointestinal tract, avoiding the severe systemic toxicities associated with other JAK inhibitors.

In a Phase 2a proof-of-concept clinical trial in patients with moderate to severe ulcerative colitis, GI-restricted OST-122 was well tolerated during the 4-week treatment period. Its excellent safety profile, minimal systemic absorption and promising clinical activity may provide a safer therapeutic option for a broad range of UC patients.

OST-499

Our second clinical program is focused on the development of OST-499, a non-steroidal progesterone receptor antagonist, for the treatment of uterine fibroids and other gynecological disorders.